Efficacy of 1-week ranitidine-bismuth-citrate (RBC)-based triple therapy for eradication of Helicobacter pylori infection.
Savarino
V
V
Vigneri
S
S
D000863:Antacids / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage*; D009942:Organometallic Compounds / Q000008:administration & dosage*; D011899:Ranitidine / Q000008:administration & dosage*
D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D008795:Metronidazole; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate